ERKAM KOCAASLAN,, FATMA ARİKAN,, ASU FERGUN YİLMAZ,, ISİK ATAGUNDUZ,, AYSE TULİN TUGLULAR,, TAYFUR TOPBAS
Eurasian Journal of Medical Investigation - 2025;9(2):72-78
Objectives: SMZL is a rare disease that typically progresses slowly. However, some patients experience poorer outcomes compared to others. Two important scoring systems have been developed to predict prognosis in SMZL. The Italian Lymphoma Intergroup (IIL) scoring system was primarily created based on a cohort of patients treated before the era of rituximab. On the other hand, the Splenic Marginal Zone Lymphoma Study Group (SMZLSG) scoring system includes patients who were treated with rituximab. Our objective was to compare these two prognostic scoring systems in terms of predicting overall survival and time-to-next treatment in SMZL patients. Methods: We classified thirty-two patients, who received various types of treatment, using both scoring systems. The risk categories defined by each scoring system were compared. Cox regression analysis was performed to evaluate the predictive value of each score on time-to-next treatment and treatment/follow-up modalities. Results: We observed that the IIL system classified more patients into higher-risk groups compared to the SMZLSG scoring system. In Cox regression analysis, the SMZLSG risk score was found to be an independent and strong predictor of time-to-next treatment and treatment/follow-up modalities (OR: 3.72, 95% CI: 1.82–7.62, p < 0.001). Conclusions: Based on our findings, we conclude that while both prognostic systems perform well, the SMZLSG scoring system provides better stratification of patients compared to the IIL system.
